Cardio drugs Flashcards
What is the antihypertensive therapy for primary (essential) HTN?
thiazide diuretics
ACE inhibitors
ARBs
dihydropyridine Ca2+ channel blockers
What is the treatment therapy for HTN with HF?
Diuretics, ACE inhibitors/ARBs, beta-blockers (compensated HF only), aldosterone antagonists
What is the treatment therapy for HTN with diabetes mellitus?
ACE inhibitors/ARBs (protective against diabetic nephropathy), Ca2+ channel blockers, thiazide diuretics, beta-blockers
What is the treatment therapy for HTN in pregnancy?
Hydralazine, labetalol, methyldopa, nifedipine
What is the mechanism of Ca2+ channel blockers?
block voltage-dependent L-type calcium channels of cardiac and smooth muscle -> decreased muscle contractility
dihydropyridines act on smooth muscle preferentially and non-dihydropyridines act on cardiac muscle preferentially
Dihydropyridine Ca2+ channel blockers - examples, mechanism, clinical use and toxicity
Amlodipine, clevidipine, nicardipine, nifedipine, nimodipine
Mechanism: block voltage-dependent L-type calcium channels of smooth muscle preferentially (minor cardiac muscle effects)
Clinical use:
all except nimodipine - HTN, angina, Raynaud phenomenon
Nimodipine - subarachnoid hemorrhage (prevents cerebral vasospasm)
Clevidipine and nicardipine: HTN urgency or emergency (BP>180/120)
Toxicity: cardiac depression, peripheral edema, flushing, dizziness, gingival hyperplasia, reflex tachycardia
Non-Dihydropyridine Ca2+ channel blockers - examples, mechanism, clinical use and toxicity
Diltiazem, verapamil
Mechanism: block voltage-dependent L-type calcium channels of cardiac muscle preferentially
Clinical use: HTN, angina, atrial fibrillation/flutter
Toxicity: cardiac depression, AV block, peripheral edema, flushing, dizziness, hyperprolactinemia (verapamil), constipation, gingival hyperplasia
Hydralazine
Mechanism: increases cGMP -> smooth muscle relaxation. Vasodilates arterioles > veins; afterload reduction
Use: HTN (especially acute), HF (with organic nitrate). Safe to use in pregnancy. Coadministered with beta-blocker to prevent reflex tachycardia
Toxicity: reflex tachycardia (contraindicated in angina/CAD), fluid retention, HA, angina, SLE-like syndrome
HTN emergency drug therapy
- Clevidipine (dihydropyridine Ca2+ channel blocker)
- Fenoldopam (D1 agonist)
- Labetalol (beta-blocker)
- Nicardipine (dihydropyridine Ca2+ channel blocker)
- Nitroprusside(increase NO release)
Nitroprusside
Mech: short acting; increases cGMP via direct release of NO
Use: HTN emergency
Toxicity: can cause cyanide toxicity
Fenoldopam
specific D1 receptor agonist-> increase cAMP -> coronary, peripheral, renal and splanchnic vasodilation
Use: HTN emergency
Only IV agent that decreases BP and IMPROVES renal function Decreases BP and increases natriuresis
nitrates
Nitroglycerin, isosorbide dinitrate, isosorbide mononitrate
Mechanism: increase NO in vascular smooth muscle -> increases cGMP and smooth muscle relaxation *dilates veins»_space; arteries –> decreases preload
Use: angina, acute coronary syndrome, pulmonary edema
Toxicity: reflex tachycardia (treat with beta-blocker), hypotension, flushing, HA, “Monday disease” in industrial exposure
Beta1-selective blockers (beta1>beta2): examples, mechanism and uses
acebutolol (partial agonist), atenolol, betaxolol, bisoprolol, esmolol, metoprolol
Mechanism: selectively block beta1 receptors -> good for patients with co-morbid pulmonary disease since beta2 blockage causes bronchoconstriction
Use:
angina -> decreases O2 consumption bu decreasing HR and contractility (acebutolol contraindicated in angina)
MI (bisoprolol, metoprolol) -> decreases mortality
SVT (esmolol, metoprolol) -> class II antiarrhythmic, decreases AV conduction velocity
HTN -> decreases CO and renin secretion
HF
Beta blockers toxicity
Impotence
cardiovascular effects (bradycardia, AV block, HF)
CNS effects (seizures, sedation, sleep alteration)
dyslipidemia (metoprolol)
asthma/COPD exacerbations (more in nonselective beta blockers)
CONTRAINDICATED in cocaine users -> can cause unopposed alpha receptor agonist activity
Nonselective alpha and beta blockers
carvedilol, labetalol
Nebivolol
cardiac selective beta1 blockage and stimulation of beta3 which activates NO in vasculature -> vasodilation
HMG-CoA reductase inhibitors
‘statins’
Mechanism: inhibit conversion of HMG-CoA to mevalonate (cholesterol precursor)
-This causes lower LDL and increased LDL receptor expression on hepatocytes -> increased LDL-receptor-mediated endocytosis of LDL -> decreased circulating LDL
Effect: decreases LDL the most, increases HDL and decreases TGs; decreases mortality in CAD patients
Toxicity: Hepatotoxicity (increases LFTs), myopathy (especially when used with fibrates or niacin)
Bile acid resins
Cholestyramine, colestipol, colesevelam
Mechanism: prevent reabsorption of bile acids -> liver uses cholesterol to make more
Effect: significantly decreases LDL, slightly increases HDL and slightly increases TGs
Toxicity: GI upset, decreased absorption of other drugs and fat-soluble vitamins
Ezetimibe
Mechanism: prevents cholesterol absorption at small intestine brush border
Effect: significant reduction in LDL, no effect on HDL or TGs
Toxicity: Rare increase in LFTs, diarrhea
Fibrates
Gemfibrozil, clofibrate, bezafibrate, fenofibrate
Mechanism: stimulates lipoprotein lipase -> upregulates LDL -> increased TG clearance; Activates PPAR-alpha to induce HDL synthesis
Effect: modest reduction in LDL, modest increase in HDL and huge decrease in TGs
Toxicity: myopathy (increased risk with statins), cholesterol gallstones
Niacin (vitamin B3)
Mechanism:
- inhibits lipolysis (hormone-sensitive lipase) in adipose tissue -> reduces TGs
- reduces hepatic VLDL synthesis -> decreased LDL
- inhibits TG synthesis in liver
- Increases HDL levels by limiting cholesterol transfer from HDL to VLDL and slowing HDL clearance
Effect: significant reduction in LDL and increase in HDL, modest reduction in TGs
Toxicity: *Red, flushed face (decreases when used with NSAID or long-term use) from release of PGD2 -> vasodilation of skin
Hyperglycemia, hyperuricemia
Digoxin - mechanism and uses
Cardiac glycoside
Mechanism: inhibits Na+/K+ ATPase -> indirectly inhibits Na+/Ca+ exchanger -> increased intracellular Ca2+-> positive inotropy. Stimulates vagus nerve (CN X) -> decreases HR
Use: HF (increases contractility), Atrial fibrillation (decreases conduction at AV node and depression of SA node)
Digoxin toxicity, factors predisposing to toxicity and antidote
Toxicity:
- Cholinergic - nausea, vomiting, diarrhea, blurry yellow vision, arrhythmias, AV block
- Can cause hyperkalemia - poor prognosis
Factors predisposing toxicity:
- Renal failure (decreased excretion)
- Hypokalemia (digoxin has more ability to bind K+ site on Na+/K+ ATPase)
- verapamil, amiodarone and quinidine decrease digoxin clearance as it displaces digoxin from binding sites
Antidote: slowly normalize K+, cardiac pacer, anti-digoxin Fab fragments, Mg2+
Angiotensin II receptor blockers (ARBs)
Losartan, candesartan, valsartan
Mechanism: selectively block binding of ATII to AT1 receptor. Similar effects to ACE inhibitors but do NOT increase bradykinin
Use: HTN, HF, proteinuria or diabetic nephropathy with intolerance to ACE inhibitors (cough, angioedema)
Toxicity: hyperkalemia, decrease renal fxn, hypotension, teratogen CONTRAINDICATED in pregnancy